Some 68% of patients with autoimmune disease had "major" side effects from CAR-T therapy for myeloma, lymphoma, or leukemia, ...

Moderna Inc. (NASDAQ:MRNA) is one of the best high volume stocks to buy according to Wall Street analysts. On October 13, ...

A research team has introduced a novel cancer immunotherapy strategy. This approach involves attaching "fake targets" to ...

mRNA-4359 combined with pembrolizumab achieved a 24% ORR and 67% efficacy in PD-L1 positive melanoma patients. The study ...

Moderna’s mRNA-4359, when used with Keytruda, achieves a 24% overall objective response rate in patients with melanoma, with ...

(NASDAQ:MRNA) today announced that clinical, safety and translational data from its Phase 1/2 study evaluating mRNA-4359 in ...